Influence of HIV infection on the clinical presentation and outcome of adults with acute community-acquired pneumonia in Yaounde, Cameroon: a retrospective hospital-based study by unknown
Pefura Yone et al. BMC Pulmonary Medicine 2012, 12:46
http://www.biomedcentral.com/1471-2466/12/46RESEARCH ARTICLE Open AccessInfluence of HIV infection on the clinical
presentation and outcome of adults with acute
community-acquired pneumonia in Yaounde,
Cameroon: a retrospective hospital-based study
Eric Walter Pefura Yone1,2*, Adamou Dodo Balkissou2, André Pascal Kengne3 and Christopher Kuaban1,2Abstract
Background: The impact of HIV infection on the evolution of acute community-acquired pneumonia (CAP) is still
controversial. The aim of this study was to investigate possible differences in the clinical presentation and
in-hospital outcomes of patients with CAP with and without HIV infection in a specialised service in Yaounde.
Methods: Medical files of 106 patients (51 men) aged 15 years and above, admitted to the Pneumology service of
the Yaounde Jamot Hospital between January 2008 and May 2012, were retrospectively studied.
Results: Sixty-two (58.5%) patients were HIV infected. The median age of all patients was 40 years (interquartile
range: 31.75-53) and there was no difference in the clinical and radiological profile of patients with and without HIV
infection. The median leukocyte count (interquartile range) was 14,600/mm3 (10,900-20,600) and 10,450/mm3
(6,400-16,850) respectively in HIV negative and HIV positive patients (p = 0.002). Median haemoglobin level
(interquartile range) was 10.8 g/dl (8.9-12) in HIV negative and 9.7 g/dl (8–11.6) in HIV positive patients (p = 0.025).
In-hospital treatment failure on third day (39.5% vs. 25.5.1%, p = 0.137) and mortality rates (9% vs. 14.5%, p = 0.401)
were similar between HIV negative and HIV positive patients.
Conclusion: Clinical and radiological features as well as response to treatment and in hospital fatal outcomes are
similar in adult patients hospitalised with acute community-acquired pneumonia in Yaounde. In contrast, HIV
infected patients tend to be more anaemic and have lower white cell counts than HIV negative patients. Larger
prospective studies are needed to consolidate these findings.
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Acute community-acquired pneumonia (CAP) is a com-
mon cause of morbidity and mortality in sub-Saharan
Africa (SSA)[1-3], where it is highly frequent in people
with HIV infection [4]. The possible effects of HIV in-
fection on the evolution of CAP are still controversial.
For instance, whether HIV infection negatively impacts
on fatal outcome in patients with CAP is still uncertain
[1,3,5-7], justifying at times the exclusion of HIV* Correspondence: pefura2002@yahoo.fr
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distribution, and reproduction in any mediumpatients from trials on CAP [6]. In spite of the proven
efficacy of empirical antibiotic treatment on CAP in
people with HIV [8-10], the management of the condi-
tion in SSA is still compromised by the lack of bacterio-
logical investigations. Moreover, the fear of pejorative
evolution often leads to frequent hospitalisation of
CAP patients with HIV, even in the absence of classical
clinical signs of severity of the disease [6].
In Cameroon, a study investigating the effects of HIV in-
fection of CAP 15 years ago, reported frequent bacter-
aemia in patients with HIV [1]. In the context of the
growing population of individuals with HIV infection in
SSA in general, the current report aims to update the
knowledge on the potential effects of HIV infection onntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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entation and in-hospital outcomes of CAP patients with
and without HIV infection in urban setting in Cameroon.
Materials and methods
Study setting and participants
The study was undertaken in the pneumology service of
the Yaounde Jamot Hospital (YJH), which has been
described in details elsewhere [11,12]. In brief, YJH
serves a referral centre for chest disease for the capital
city of Cameroon (Yaounde) and surrounding areas.
CAP in this hospital is diagnosed based on 1) lower re-
spiratory tract infection signs, 2) new alveolar opacity on
chest X-ray and 3) the absence of other possible causes of
the alveolar opacity [13]. All chest X-rays are read by radi-
ologist and reviewed by treating chest physician. Patients
with radiological signs suggestive of other possible causes,
or in whom radiological signs do no regress on treatment
are prescribed a bronchial fibroscopy to rule out tubercu-
losis and others opportunistic infections. Upon admission
to this hospital, routine evaluation of patients suspected of
having CAP received include a clinical examination, chest
X-ray (frontal and lateral views), sputum examination for
Acid Fast Bacillus (AFB) in patients who can produce a
sputum (three series at the beginning of the treatment and
three series at the completion of the treatment) and bio-
logical workup comprising a full blood count, fasting gly-
caemia, erythrocyte sedimentation rate and HIV test after
informed consent. HIV testing includes detection of anti-
HIV 1 and anti-HIV 2 antibodies in the serum with the
use of two rapid tests: DetermineW HIV ½(Abbot labora-
tories, Tokyo, Japan) and ImmunocombW II HIV 1 and 2
Bispot (Organics, Courbevoie, France). A patient is classi-
fied as HIV positive when the two tests are positive. For
discordant tests, a confirmatory western blot test (New
Lav Blot, Sanofi diagnostics-Pasteur) is conducted. All
HIV-positive patients are started on prophylaxis with
cotrimoxazole and those with CD4 lymphocyte counts <
200/mm3 or with recurrent pneumonia (at least 2 epi-
sodes within a 12 month window) are started on triple
antiretroviral therapy free of charge.
On admission to the service, patients are treated empir-
ically with a betalactam antibiotic and treatment is
adjusted according to patients’ clinical response. Bacterio-
logical investigations to isolate the microbial aetiology are
hardly ever done because of limited resources and lack of
diagnostic facilities. Monitoring is based on daily assess-
ment of the clinical profile including body temperature,
and chest X-ray on the tenth day from treatment inception
in those with favourable treatment course. Favourable re-
sponse to treatment on the third day is defined by the re-
gression of lower respiratory tract infection signs and
particularly thermic defervescence or body temperature
normalisation [13]. Treatment failure at this same timepoint is based on the non-abatement of the fever and wor-
sening of chest signs. Patients with treatment failure are
re-assessed for differential diagnoses, loco-regional com-
plications (lung abscess, purulent or parapneumonic
pleural effusion), extra-pulmonary infection and bacterial
resistance to the initial empirical treatment.
All the patients admitted in the service are indexed by
the chief nurse of each hospitalization unit as their arrival
in hospitalization registers envisaged for this purpose. For
each in-patient, the following elements are consigned in
the registers: age, sex, admission and discharge date,
results of HIV serology, admission and discharge diagnosis.
Methods
Recruitment for this study was restricted to patients aged
15 years and above, followed for CAP at any time point
during January 2008 through May 2012 (total duration
53 months). Patients’ hospitalisation registers were
reviewed to identify those who were hospitalised for CAP
and their medical files were then retrieved. For all eligible
patients, data were collected on the demographic profile
including sex and age, past medical history and comor-
bidities, and disease course prior to hospital admission.
Clinical signs and symptoms recorded included the body
temperature (with fever defined as a temperature ≥38°C),
cough, chest pain, dyspnoea, haemoptysis, respiratory and
heart rates, and condensation syndrome. The CRB-65
score [14] presented by each patient at the admission was
noted. Standard chest X-ray data upon admission and
subsequently were analysed and the following registered:
unilateral or bilateral lung parenchyma lesions and num-
ber of lobes involved, presence or absence of pleural effu-
sion. Biological data included the full blood count, HIV
test results, and CD4 count for HIV positive patients.
Evolution data included those relating to treatment failure
at day three following inception, local and regional com-
plications, treatment success and all-cause mortality.
Patients with missing data for HIV status and those with
missing medical file were excluded. The study protocol
was approved by the institutional board of the YJH.
Statistical methods
Data analysis used SPSSW 17.0.1 (SPSS Inc., Chicago,
USA) for Windows. Groups comparison used Pearson χ2
or Fisher exact test for qualitative variables, and Student
t-test or non prametric equivalents for quantitative vari-
ables as appropriate. A p-value <0.05 was used to char-
acterise statistically significant results.
Results
Data available
During the study period, a total of 6098 patients were
admitted to the service, among whom 118 (1.9%)
patients aged ≥ 15 years had CAP. Medical files were
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For those with medical file available, six were excluded
for missing data on HIV status. Therefore 106 patients
(51 being men) with a median age of 40 years (interquar-
tile range: 31.75-53) were included in the final analysis.
To validate the selection process, medical files were also
retrieved for a random sample of 100 patients who did
not have CAP based on registers. None of them also had
CAP based on the diagnosis in the medical file. For those
patients included data were missing for few participants
on some variables and are reported where relevant.
Prevalence of HIV infection and treatment
Of the 106 patients included 62 (58.5%) were HIV posi-
tive, all being infected with HIV-1 serotype. The median
CD4 lymphocyte count in those with HIV infection was
211/mm3 (interquartile range: 97.5-331). Twenty-one
(33.9%) HIV-infected patients had CD4 count lower than
200/mm3. HIV infection had been diagnosed prior hos-
pital admission in 28 (45.2%) of them, and 18 (29%) were
on antiretroviral therapy.Table 1 Clinical, radiological and hematologic characteristics




≤ 40, n (%) 21 (47.7)
> 40, n (%) 23 (52.3)
Chest symptoms
Cough, n(%) 43/43(100)
Expectoration, n (%) 34/42 (81)
Chest pain, n (%) 42 (95.5)
Dyspnoea, n (%) 26 (59.1)
Duration of symptoms , median(IQR) 10 (7-17)
CRB65 Score
< 2, n (%) 33/40(82.5)
≥ 2, n (%) 7/40 (17.5)
Past medical History
Smoking, n (%) 10 (22.7)
Excessive alcohol consumption, n (%) 10/42 (23.8)
Other comorbidities, n (%) 7 (15.9)
Radiographic features
Single lobe involvement, n (%) 17 (35.5)
Multiple lobes involvement, n (%) 27 (64.5)
Pleural effusion, n (%) 10 (22.7)
Hematologic features
Median leucocytes count, mm3 (IQR) 14,600 (10,900-20,
Median haemoglobin, g/dl (IQR) 10.8 (8.9-12)
Mean platelet count, mm3 (SD) 302,880 (129,588)
IQR, interquartile range; SD, standard deviation.Profile of patients by HIV status upon admission
Clinical, radiological and biological characteristics of
HIV positive and HIV negative participants are
described in Table 1. The two groups were broadly
similar with regard to demographic, past medical his-
tory, clinical and radiological profiles. Differences were
however apparent in the biological profile where
patients with HIV infection had lower haemoglobin
levels (9.7 vs. 10.8 g/dl, p = 0.025) and lower total leuco-
cyte count (10,450 vs. 14,600, p = 0.003) than HIV nega-
tive patients (Table 1).
Outcomes of patients with and without HIV infection
Non-significantly high rate of treatment failure was
recorded in HIV negative, as compared to HIV positive
patients (35.5% vs. 25.5%, p = 0.137). Loco-regional com-
plications were also more likely to occur in HIV negative
patients (40.1%) than among the HIV positive ones
(17.7%) (p = 0.008, Table 2). In both groups, the most
frequent complication was purulent pleural effusion,
which occurred in 7 (15.9%) HIV negative patients and 5of patients with acute community-acquired pneumonia,

















600) 10,450 (6,400-16,850) 0.003
9.7 (8-11.6) 0.025
259,550 (140,148) 0.116
Table 2 Evolution of patients with acute community-acquired pneumonia, possibly of bacterial origin in Yaounde
Evolution HIV negative n=44 HIV positive n=62 p-value
Treatment failure on 3rd day*, n (%) 17/43 (33.3) 14/55 (17.1) 0.137
Loco-regional complications
None, n (%) 26 (59.1) 51 (82.3) 0.008
Parapneumonic pleural effusion, n (%) 5 (11.4) 3 (4.8) 0.271
Purulent pleural effusion, n (%) 7 (15.9) 5 (8.1) 0.229
Lung abscess, n (%) 6 (13.6) 3 (4.8) 0.158
Median duration of hospitalisation, days (IQR) 13 (10-15) 11.5 (8-16) 0.554
Death, n (%) 4 (9.0) 9 (14.5) 0.401
Median time to death, days (IQR) 0.54 (0.15-6.45) 2 (1-10) 0.268
* One HIV negative and seven HIV positive patients had deceased before 3rd day; IQR, interquartile range.
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hospitalisation (interquartile range) was 13 (10–15) days
in HIV negative patients and 11.5 (8–16) in HIV positive
patients (p = 0.554, Table 2). Death rate during this
period and median time to death were similar between
the two groups (both p ≥ 0.268).
Discussion and conclusions
In this study conducted in a major referral hospital for
chest diseases in Cameroon, we found a high prevalence
of HIV-1 infection among patients admitted for acute
community-acquired pneumonia. Half of the time, HIV
infection was undiagnosed at the time of clinical presen-
tation with CAP. Among those already diagnosed with
HIV infection, about half were on antiretroviral therapy.
With three exceptions, the clinical, radiological, bio-
logical profiles of patients and outcomes of care for CAP
were similar between patients with HIV infection and
those without. These exceptions relate to the low
haemoglobin level and low total leucocytes counts in
HIV positive patients and a high complication rates
among HIV negative patients.
The prevalence of HIV infection in our study is about
the double of the prevalence rate reported in Cameroon
15 years ago [1] based on 110 patients recruited from
three different hospitals, probably mirroring the chan-
ging prevalence of HIV in the country between the two
study periods. Indeed, available data suggest that HIV
prevalence was about 3% at the general population in
Cameroon in 1994 [15], and increased to about 5% in
2007 [16]. Otherwise, HIV prevalence in our study was
closer to the 58% rate reported by Horo et al. in Ivory
Coast [3].
While the well-known young age of patients with HIV
may explain part of the findings, our study suggests that
hospitalised patients with CAP in this setting were pre-
dominantly young individuals. This may reflect the over-
all young age of the general population. The equal
distribution of women among HIV negative and HIV
positive patients suggests that high rates of HIVinfections among women in Africa [16] may not neces-
sarily translated into more women with HIV developing
CAP. Such a claim however, based on a hospital cohort
remains very weak in the context of many uncontrolled
sources of biases. The broadly comparable clinical and
radiological profiles of patients with and without HIV
infection found in our study is in agreement with exist-
ing reports[1,3]. Of note, the disease severity as assessed
by the CRB-65 score [14] was unaffected by HIV status.
Differences found in the haematological profile were
largely expected. For instance, it is well known that an-
aemia is of multifactorial causes in the context of HIV
infection, and is not necessarily correlated with
immune-depression and presence of opportunistic infec-
tions [17,18].
The comparable evolution and outcomes of patients
regardless of their status for HIV in our sample is largely
in agreement with earlier report from the same setting
[1]. The high prevalence of loco-regional complications
among HIV negative participants in this study is possibly
related to a high prevalence of infections due to necro-
tizing micro-organisms in this subgroup. Indeed, in a re-
cent study on purulent pleural effusions in the same
setting, we found that Staphylococcus aureus micro-
organism was more frequently isolated in HIV negative
than in HIV positive patients (23.8% vs. 12.5%), although
the difference was not statistically significant, due to the
small sample [19]. However, death rate among our much
large sample of patients with HIV infection was likely
higher than the 7% reported previously based on half the
size of our cohort with HIV [1]. Discrepancies are likely
due to difference in precisions on the diagnosis of CAP.
The former study [1] used microbiological investigations
for diagnosis confirmation and accordingly adapting
treatments, what our study did not afford. In over half of
patients with fatal outcomes in our sample, death oc-
curred with the first 72 h of observation needed to as-
sess the response to treatment. Some would have been
the result of inappropriate initial diagnosis or inefficacy
of the empirical treatment. In general mortality rate
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varies substantially [5,7,8,20-22]. However, available
studies on the effect of HIV on fatal outcome in patients
with CAP are conflicting with some suggesting a less
favourable outcome in patients with severe immune de-
pression [5,21,23], and others suggesting no effect of im-
mune depression on mortality [1,6,7,23]. In a study by
Feldman et al. [24] in HIV positive patients with baterie-
mic pneumococcal pneumonia, fatality rate was high in
patients with severe immune-depression. We instead
found no significant difference in death rates among
patients CAP patients with HIV according to the severity
of the disease (data not shown).
Our study has some limitations including the retro-
spective nature and as a result data were missing for
some participants on some variables including key inclu-
sion variables such as HIV status, HIV viral load and
other variables like nutitional and socioeconomic status.
In the absence of microbiological investigations, we were
unable to have a definitive confirmation of diagnosis. In
this context, some patients would have probably been
misclassified as having CAP or not, which may have the
undesirable effect of biasing the results if occurring in a
differential ways. The previous study in this setting sug-
gests using microbiological diagnosis as a standard, phy-
sicians diagnosis of pneumonia is accurate in about 50%
of cases, and similarly among patients with HIV and
those without [1]. The strengths of our study include the
relatively larger number of people with HIV and accord-
ingly more power to investigate the effects of prior
knowledge of HIV status on clinical presentation and
outcome of care for CAP.
In conclusion, HIV infection is highly frequent among
patients with CAP in this setting. In major ways how-
ever, it seems to be unrelated with key aspects of the dis-
ease including clinical presentation, radiological findings,
response to empirical antibiotic treatment and fatal out-
comes. Therefore similar strategies should be applied to
CAP patients regardless of the status for HIV. However,
CAP presentation should be used as an opportunity to
screen individuals for undiagnosed HIV infection. Larger
prospective studies and needed to consolidate these
findings.
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